Form 4: Olema Pharmaceuticals Director Cyrus Harmon Acquires 23,000 Stock Options
SEC Form 4 Filing
Director Cyrus Harmon acquired 23,000 stock options in Olema Pharmaceuticals, Inc. on June 14, 2024.
Summary
- Cyrus Harmon, a director of Olema Pharmaceuticals, Inc., acquired 23,000 stock options on June 14, 2024.
- The options have an exercise price of $12.36.
- The options vest in 12 equal monthly installments starting from June 14, 2024, and expire on June 14, 2034.
- Full vesting will occur at the next annual meeting if not fully vested before, contingent on continuous service.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. It's common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, as the value of the options increases with the company's stock price.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of earliest transaction: Grant of 23,000 stock options. |
| 06/14/2024 | Vesting start date for the stock options. |
| 06/14/2034 | Expiration date for the stock options. |
| 06/18/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.